These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18684820)

  • 1. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol.
    Bouvier NM; Lowen AC; Palese P
    J Virol; 2008 Oct; 82(20):10052-8. PubMed ID: 18684820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.
    Marjuki H; Mishin VP; Chesnokov AP; De La Cruz JA; Davis CT; Villanueva JM; Fry AM; Gubareva LV
    J Virol; 2015 May; 89(10):5419-26. PubMed ID: 25740997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.
    Ives JA; Carr JA; Mendel DB; Tai CY; Lambkin R; Kelly L; Oxford JS; Hayden FG; Roberts NA
    Antiviral Res; 2002 Aug; 55(2):307-17. PubMed ID: 12103431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.
    Sheu TG; Deyde VM; Okomo-Adhiambo M; Garten RJ; Xu X; Bright RA; Butler EN; Wallis TR; Klimov AI; Gubareva LV
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3284-92. PubMed ID: 18625765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.
    Herlocher ML; Truscon R; Elias S; Yen HL; Roberts NA; Ohmit SE; Monto AS
    J Infect Dis; 2004 Nov; 190(9):1627-30. PubMed ID: 15478068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors.
    Hatakeyama S; Sugaya N; Ito M; Yamazaki M; Ichikawa M; Kimura K; Kiso M; Shimizu H; Kawakami C; Koike K; Mitamura K; Kawaoka Y
    JAMA; 2007 Apr; 297(13):1435-42. PubMed ID: 17405969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo.
    Carr J; Ives J; Kelly L; Lambkin R; Oxford J; Mendel D; Tai L; Roberts N
    Antiviral Res; 2002 May; 54(2):79-88. PubMed ID: 12062393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivir.
    Richard M; Ferraris O; Erny A; Barthélémy M; Traversier A; Sabatier M; Hay A; Lin YP; Russell RJ; Lina B
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2942-52. PubMed ID: 21422222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An I436N substitution confers resistance of influenza A(H1N1)pdm09 viruses to multiple neuraminidase inhibitors without affecting viral fitness.
    Kwon JJ; Choi WS; Jeong JH; Kim EH; Lee OJ; Yoon SW; Hwang J; Webby RJ; Govorkova EA; Choi YK; Baek YH; Song MS
    J Gen Virol; 2018 Mar; 99(3):292-302. PubMed ID: 29493493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.
    Abed Y; Baz M; Boivin G
    J Infect Dis; 2009 Jan; 199(2):180-3. PubMed ID: 19046066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
    Molla A; Kati W; Carrick R; Steffy K; Shi Y; Montgomery D; Gusick N; Stoll VS; Stewart KD; Ng TI; Maring C; Kempf DJ; Kohlbrenner W
    J Virol; 2002 Jun; 76(11):5380-6. PubMed ID: 11991966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistant influenza A viruses in children treated with oseltamivir: descriptive study.
    Kiso M; Mitamura K; Sakai-Tagawa Y; Shiraishi K; Kawakami C; Kimura K; Hayden FG; Sugaya N; Kawaoka Y
    Lancet; 2004 Aug 28-Sep 3; 364(9436):759-65. PubMed ID: 15337401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact on antiviral resistance of E119V, I222L and R292K substitutions in influenza A viruses bearing a group 2 neuraminidase (N2, N3, N6, N7 and N9).
    Gaymard A; Charles-Dufant A; Sabatier M; Cortay JC; Frobert E; Picard C; Casalegno JS; Rosa-Calatrava M; Ferraris O; Valette M; Ottmann M; Lina B; Escuret V
    J Antimicrob Chemother; 2016 Nov; 71(11):3036-3045. PubMed ID: 27432605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.
    Zürcher T; Yates PJ; Daly J; Sahasrabudhe A; Walters M; Dash L; Tisdale M; McKimm-Breschkin JL
    J Antimicrob Chemother; 2006 Oct; 58(4):723-32. PubMed ID: 16891631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced airborne transmission of oseltamivir-resistant pandemic A/H1N1 virus in ferrets.
    Hamelin ME; Baz M; Bouhy X; Beaulieu E; Dubé K; Mallett C; Boivin G
    Antivir Ther; 2011; 16(5):775-9. PubMed ID: 21817200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dextran sulfate-resistant A/Puerto Rico/8/34 influenza virus is associated with the emergence of specific mutations in the neuraminidase glycoprotein.
    Yamada H; Nagao C; Haredy AM; Mori Y; Mizuguchi K; Yamanishi K; Okamoto S
    Antiviral Res; 2014 Nov; 111():69-77. PubMed ID: 25234090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2.
    Trebbien R; Christiansen CB; Fischer TK
    J Clin Virol; 2018 May; 102():1-6. PubMed ID: 29448067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance.
    Jiang L; Liu P; Bank C; Renzette N; Prachanronarong K; Yilmaz LS; Caffrey DR; Zeldovich KB; Schiffer CA; Kowalik TF; Jensen JD; Finberg RW; Wang JP; Bolon DNA
    J Mol Biol; 2016 Feb; 428(3):538-553. PubMed ID: 26656922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global transmission of oseltamivir-resistant influenza.
    Moscona A
    N Engl J Med; 2009 Mar; 360(10):953-6. PubMed ID: 19258250
    [No Abstract]   [Full Text] [Related]  

  • 20. Progressive emergence of an oseltamivir-resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient.
    Hurt AC; Leang SK; Tiedemann K; Butler J; Mechinaud F; Kelso A; Downie P; Barr IG
    Influenza Other Respir Viruses; 2013 Nov; 7(6):904-8. PubMed ID: 23551973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.